26 August 2015 - Crohn’s disease patients can now get routine access to treatment with Takeda’s biologic Entyvio on the National Health Service in England and Wales after a full green light from cost regulators.

The National Institute for Health and Care Excellence has published final guidelines endorsing Entyvio (vedolizumab) as a treatment for adult patients with moderately to severely active Crohn’s who have either failed or can’t take anti-TNF therapy.

Enytvio is a novel alpha-4 beta-7 integrin antagonist with a different mode of action to other therapies in that it suppresses immune activity only in the gut as opposed to across the whole body, which experts see as “a step change” in the management of the condition.

Indeed, clinical experts consulted by NICE agreed that Entyvio had a more favourable adverse-event profile than other biological treatments because of its ‘gut-specific’ effect and fewer systemic side effects, according to Takeda.

For more details, go to: http://www.pharmatimes.com/Article/15-08-26/Final_NICE_green_light_for_Takeda_s_Entyvio.aspx